Contract Win

AI SummaryClose X

Fusion Antibodies PLC announced on August 28, 2025, that it has been awarded a new humanisation project under an existing Master Service Agreement with a US-based specialty division of a global pharmaceutical company. The company anticipates generating modest revenues from this Humanisation Project, which is expected to be completed within the current financial year. This contract win is strategically important as it demonstrates Fusion's ability to secure contracts with major pharmaceutical companies and reduce reliance on smaller clients. The project also allows Fusion to leverage its novel technologies, such as OptiMAL®.

Disclaimer*

UK 100

Latest directors dealings